摘要
目的检测SOX10、EGFR蛋白在浸润性三阴性乳腺癌患者的组织标本中的表达情况,分析其与患者临床病理特征的关系及预后价值。方法回顾性分析2012年1月至2021年10月于我院诊治的80例乳腺癌患者资料,收集所有患者的乳腺癌组织标本,采用免疫组织化学染色法(IHC)检测乳腺癌组织中SOX10、EGFR蛋白表达情况,分析SOX10阳性表达与阴性表达两组患者的EGFR蛋白表达水平差异,并分析SOX10、EGFR与乳腺癌患者临床病理特征的相关性,探讨SOX10、EGFR表达水平对患者总体生存(OS)的影响。通过COX多因素回归分析影响患者OS的独立危险因素。结果不同年龄、肿瘤分化程度的乳腺癌患者组织中SOX10、EGFR阳性表达率差异均无统计学意义(P均>0.05),肿瘤大小≥2cm、TNM分期为II/III期、存在淋巴结转移的患者较肿瘤大小<2cm、TNM分期为I期、无淋巴结转移者SOX10、EGFR阳性表达率更高,差异具有统计学意义(P均<0.05)。SOX10阳性表达组的EGFR表达率为74.4%(29/39),较阴性组24.4%(10/41)的高,差异具有统计学意义(χ^(2)=19.975,P<0.001)。单因素分析结果显示,TNM分期、肿瘤最大径、淋巴结转移状态、SOX10、EGFR的表达水平是影响患者OS的因素(P=0.013、0.027、<0.001、0.015、<0.001),多因素分析结果显示,TNM分期、淋巴结转移状态、SOX10和EGFR的表达是影响患者OS的独立危险因素(P=0.020、0.042、0.037、0.032)。SOX10阳性表达组患者的中位OS为17个月,显著低于阴性表达组的37个月,差异具有统计学意义(HR=2.078,95%CI 1.217~3.543,P=0.004),EGFR阳性表达组患者的中位OS为20.5个月,显著低于阴性表达组的36个月,差异具有统计学意义(HR=1.819,95%CI 1.074~3.083,P=0.019)。结论SOX10和EGFR可能存在共表达关系,且两者的表达情况与乳腺癌的进展密切相关,均可作为患者预后评估的分子标志物。
Objective To detect expressions of SOX10 and EGFR proteins in tissue samples of patients with invasive triple negative breast cancer,and to analyze their relationships with clinicopathological characteristics and related prognostic value.Methods The data of 80 patients with breast cancer diagnosed and treated in our hospital from January,2012 to October,2021 were retrospectively analyzed.Breast cancer tissue samples of all patients were collected.Expressions of SOX10 and EGFR proteins in breast cancer tissue were detected by immunohistochemical staining(IHC).We explored the impact of SOX10 and EGFR expression levels on overall survival(OS)of patients.Independent risk factors affecting patient OS were analyzed through COX multivariate regression analysis.Results There was no significant difference in the positive expression rates of SOX10 and EGFR in breast cancer tissues of different ages and tumor differentiation degrees(P>0.05).The positive expression rates of SOX10 and EGFR were higher in patients with tumor size≥2cm,TNM stage II/III,and lymph node metastasis than in patients with tumor size<2cm,TNM stage I,and no lymph node metastasis(P<0.05).EGFR expression rate of the SOX10 positive expression group was 74.4%(29/39),which was higher than the negative group of 24.4%(10/41),and the difference was statistically significant(chi square value=19.975,P<0.001).The results of univariate analysis showed that TNM stage,maximum tumor diameter,lymph node metastasis status,SOX10,and EGFR expression levels were factors affecting patient OS(P=0.013,0.027<0.001,0.015<0.001).The results of multivariate analysis showed that TNM stage,lymph node metastasis status,SOX10,and EGFR expression were independent risk factors affecting patient OS(P=0.020,0.042,0.037,0.032).The median OS of patients in the SOX10 positive expression group was 17 months,significantly lower than that of the negative expression group at 37 months(HR=2.078,95%CI 1.217-3.543,P=0.004).The median OS of patients in the EGFR positive expression group was 20.5
作者
成兰云
严晓苓
杨峰燕
邢晨阳
冀楠
陈文换
路平
CHENG Lanyun;YAN Xiaoling;YANG Fengyan;XING Chenyang;JI Nan;CHEN Wenhuan;LU Ping(Department of Pathology,Zhuozhou Hospital,Zhuozhou 072750,China)
出处
《标记免疫分析与临床》
CAS
2023年第7期1177-1181,共5页
Labeled Immunoassays and Clinical Medicine
基金
2021年度保定市科技计划自筹经费项目(编号:2141ZF340)。
关键词
乳腺癌
SOX10
EGFR
临床病理特征
预后
Breast cancer
SOX10
EGFR
Clinical pathological characteristics
Prognosis
